TOP TEN perturbations for 1541_f_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1541_f_at
Selected probe(set): 208548_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1541_f_at (208548_at) across 6673 perturbations tested by GENEVESTIGATOR:

dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):6.857848
Number of Samples:7 / 8
Experimental dendritic cell study 6 (gardiquimod)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):6.6452074
Number of Samples:4 / 8
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)

Relative Expression (log2-ratio):6.0209503
Number of Samples:4 / 4
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (CpG A; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

dendritic cell study 6 (CpG A) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):4.198983
Number of Samples:7 / 8
Experimental dendritic cell study 6 (CpG A)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

dendritic cell study 6 (CpG A; RN486) / dendritic cell study 6 (CpG A)

Relative Expression (log2-ratio):-3.574726
Number of Samples:4 / 7
Experimental dendritic cell study 6 (CpG A; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (CpG A)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; glioblastoma, NOS; primary)

Relative Expression (log2-ratio):0.9836502
Number of Samples:2 / 3
Experimental CNS cancer study 1 (PDX; glioma, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted).
Control CNS cancer study 1 (PDX; glioblastoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioblastoma, NOS of the central nervous system (subcutaneously implanted).

Olea pollen extract study 1 (allergic; pollen season) / Olea pollen extract study 1 (non-allergic; pollen season)

Relative Expression (log2-ratio):0.5221062
Number of Samples:3 / 2
Experimental Olea pollen extract study 1 (allergic; pollen season)
Peripheral blood mononuclear cells (PBMC) obtained during pollen season (April-June) from pollen-allergic patients were cultured for 24 hours in the presence of whole olive pollen extract (25µg/ml). The patients fulfilled the following criteria: seasonal rhinitis and/or asthma, a positive skin prick test for O. europaea pollen extract, and no previous immunotherapy. Each sample represents equimolar amounts of RNA from two subjects, samples were pooled prior labeling and hybridization. (Warning: Experiment with gender bias).
Control Olea pollen extract study 1 (non-allergic; pollen season)
Peripheral blood mononuclear cells (PBMC) obtained during pollen season (April-June) from patients with no history of respiratory allergies were cultured for 24 hours in the presence of whole olive pollen extract (25µg/ml). All subjects underwent skin prick test for olive pollen allergy with whole O. europaea extract and a battery of common allergens. Each sample represents equimolar amounts of RNA from two subjects, samples were pooled prior labeling and hybridization. (Warning: Experiment with gender bias).

necrotizing myopathy study 2 / inclusion body myositis study 2

Relative Expression (log2-ratio):0.5156679
Number of Samples:2 / 5
Experimental necrotizing myopathy study 2
Quadriceps femoris biopsy muscle samples from patients with clinical diagnosis of necrotizing myopathy (NM).
Control inclusion body myositis study 2
Quadriceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).

glioma study 17 (oligodendroglioma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):-0.5138869
Number of Samples:3 / 4
Experimental glioma study 17 (oligodendroglioma; unsorted)
Brain cells isolated from low grade oligodendroglioma (grade II). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 39 ± 9 years old.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):0.4628868
Number of Samples:2 / 4
Experimental R547 study 1 (24h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.